Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte(TM) in Treatment of Cutaneous T-Cell Lymphoma

Stock Information for Soligenix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Soligenix Inc.

Positive Clinical Results from HyBryte(TM) Comparative Study Evaluating HyBryte(TM) Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
HyBryte(TM) Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.
Soligenix Announces HyBryte(TM) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.